SplashBIO™

About SplashBIO™

Better trial enrollment begins before screening. SplashBIO™ is a biomarker-driven enrollment infrastructure platform — pre-screening built on biomarker science to reduce screen failures and accelerate clinical trial enrollment. Biomarkers increasingly decide who is eligible for a trial, and the field is moving those decisions upstream. Enrollment infrastructure has to move with it. SplashBIO brings an objective biomarker signal to the very front of the trial — before a patient ever reaches a site — so sponsors and sites receive a biomarker-enriched, trial-ready population. One workflow, from first contact to enrollment: • Connect — Participants enter through research, site, advocacy, and digital pathways. • Validate — Pre-screen using integrated biomarker and digital assessments. • Assess — Multi-modal evaluations generate a richer, more complete participant profile. • Enroll — Biomarker-enriched, trial-ready participants referred to sites. Built by the team behind Splash Clinical — with more than 15 years modernizing trial enrollment — SplashBIO is an independent platform company created for the biomarker era. Our initial focus is Alzheimer’s disease and neurology research, among the most challenging areas for trial enrollment, with a platform designed for broader application across future therapeutic areas. Results support enrollment matching and are not a diagnosis; eligibility is confirmed through the site's protocol screening. Screen smarter. Enroll faster. Request a Conversation — a 20-minute intro call, no pitch, no commitment — at splash-bio.com.